Begin main content

Rituxan for Acute Lymphoblastic Leukemia – Details

Project Number pCODR 10102
Brand Name Rituxan
Generic Name Rituximab
Strength 200mg and 500mg vials
Tumour Type Leukemia
Indication Acute Lymphoblastic Leukemia
Funding Request In combination with standard of care chemotherapy for Philadelphia chromosome negative, CD20 antigen positive, B-cell precursor acute lymphoblastic leukemia in adults
Review Status Under Review
Pre Noc Submission Yes
NOC Date N/A
Manufacturer Hoffmann-La Roche Limited
Submitter Cancer Care Manitoba
Submission Date February 13, 2017
Submission Deemed Complete February 21, 2017
Submission Type New Drug
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ February 28, 2017
Check-point meeting April 12, 2017
pERC Meeting (target date) June 15, 2017
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.